PITTSBURGH, Oct. 3 /Xinhua-PRNewswire/ -- Mylan Inc. (NYSE: MYL) today announced the appointment of Rajiv Malik as Executive Vice President in charge of Global Technical Operations. Mr. Malik has served in a similar capacity for Mylan since the Company acquired a controlling stake in Matrix Laboratories Limited (Matrix), where he is Chief Executive Officer, in January 2007.
As Head of Global Technical Operations, Mr. Malik will oversee the Company's global research and development (R&D) centers and manufacturing and distribution units, with responsibility for enhancing and rationalizing Mylan's global supply chain and expanded product pipeline, as well as leveraging Matrix, one of the world's largest suppliers of active pharmaceutical ingredients, across the enlarged company.
Mr. Malik has worked more than 24 years in the global generic pharmaceutical industry. In addition to his role at Mylan, Mr. Malik currently serves as Managing Director and Chief Executive Officer of Matrix. Prior to joining Matrix in 2005, he was Head of Global Development and Regulatory at Sandoz. He started his career in R&D at Ranbaxy Laboratories, rising to Head of Generics R&D.
Mylan's Vice Chairman and CEO Robert J. Coury commented, "Rajiv has been an invaluable addition to the Mylan management team since joining us in January. Since the close of the Matrix transaction, he has truly proven his capabilities and has been instrumental in the successful integration of Matrix. Rajiv has built an outstanding operational infrastructure that will allow us to capitalize on the efficiencies, synergies and sourcing opportunities we see from bringing together all three companies."
Mr. Malik earned his master's degree in pharmaceutical technology from Punjab University and has more than 60 process patents to his credit.
Mylan Inc. is one of the world's leading quality generic and specialty pharmaceutical companies. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Through its controlling interest in Matrix Laboratories Limited, Mylan has direct access to one of the largest active pharmaceutical ingredient (API) manufacturers in the world. Dey L.P., Mylan's fully integrated specialty business, provides the Company with innovative and diversified opportunities in the respiratory and allergy therapeutic areas.
For more information about Mylan, please visit http://www.mylan.com .
